Latest Close
$102.45
News
PTGX
Protagonist Therapeutics, Inc. News
This news view pulls recent coverage and headlines tied to PTGX.
1y Change
$59.88 (+140.66%)
Market Cap
$6.54B
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge
Simply Wall St. • Apr 4, 2026
Read articleTakeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment
Insider Monkey • Apr 3, 2026
Read articleProtagonist Therapeutics Insider Sold Shares Worth $2,520,000, According to a Recent SEC Filing
MT Newswires • Mar 30, 2026
Read articleProtagonist Therapeutics Insider Sold Shares Worth $2,581,504, According to a Recent SEC Filing
MT Newswires • Mar 30, 2026
Read articleProtagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
ACCESS Newswire • Mar 28, 2026
Read articleDo Protagonist Therapeutics’ (PTGX) Derisked Drugs Have Blockbuster Potential?
Insider Monkey • Mar 27, 2026
Read article